TNF inhibitor suppresses bone metastasis in a breast cancer cell line

Biochemical and Biophysical Research Communications

Volumn 407, Issue 3, 2011, Pages 525-530

  Hamaguchi, Takahiko ^a   Wakabayashi, Hiroki ^a   Matsumine, Akihiko ^a   Sudo, Akihiro ^a   Uchida, Atsumasa ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone metastasis; Breast cancer; Infliximab; MDA MB 231; Tumor necrosis factor alpha

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; DECORIN; INFLIXIMAB; PROTEOGLYCAN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; BONE METASTASIS; BREAST CANCER; CANCER CELL CULTURE; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; RECEPTORS, CXCR4; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MURINAE;

EID: 79954614542     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.03.051     Document Type: Article

References (32)

1. Bellahcene A., Kroll M., Liebens F., Castronovo V. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. J. Bone Miner. Res. 1996, 11:665-670.
2. Braun S., Vogl F.D., Naume B., Janni W., Osborne M.P., Coombes R.C., Schlimok G., Diel I.J., Gerber B., Gebauer G., Pierga J.Y., Marth C., Oruzio D., Wiedswang G., Solomayer E.F., Kundt G., Strobl B., Fehm T., Wong G.Y., Bliss J., Vincent-Salomon A., Pantel K. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 2005, 353:793-802.
3. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997, 69:1-18.
4. Balkwill F. Tumor necrosis factor or tumor promoting factor?. Cytokine Growth Factor Rev. 2002, 13:135-141.
5. Lejeune F.J., Ruegg C., Lienard D. Clinical applications of TNF-alpha in cancer. Curr. Opin. Immunol. 1998, 10:573-580.
6. Hoare S., Balkwill F., Talbot D.C., Ganesan T.S., Harris A.L. A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin. Cancer Res. 2004, 10:6528-6534.
7. Kishimoto T., Akira S., Narazaki M., Taga T. Interleukin-6 family of cytokines and gp130. Blood 1995, 86:1243-1254.
8. Asgeirsson K.S., Olafsdóttir K., Jónasson J.G., Ogmundsdóttir H.M. The effects of IL-6 on cell adhesion and e-cadherin expression in breast cancer. Cytokine 1998, 10:720-728.
9. Sheen-Chen S.M., Chen W.J., Eng H.L., Chou F.F. Serum concentration of tumor necrosis factor in patients with breast cancer. Breast Cancer Res. Treat. 1997, 43:211-215.
10. Knight D.M., Trinh H., Le J., Siegel S., Shealy D., McDonough M., Scallon B., Moore M.A., Vilcek J., Daddona P., et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol. 1993, 30:1443-1453.
11. Scallon B.J., Moore M.A., Trinh H., Knight D.M., Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995, 7:251-259.
12. Baert F.J., D'Haens G.R., Peeters M., Hiele M.I., Schaible T.F., Shealy D., Geboes K., Rutgeerts P.J. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999, 116:22-28.
13. D'Haens G., Van Deventer S., Van Hogezand R., Chalmers D., Kothe C., Baert F., Braakman T., Schaible T., Geboes K., Rutgeerts P. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999, 116:1029-1034.
14. Araki K., Wakabayashi H., Shintani K., Morikawa J., Matsumine A., Kusuzaki K., Sudo A., Uchida A. Decorin suppresses bone metastasis in a breast cancer cell line. Oncology 2009, 77:92-99.
15. Rumora L., Shaver A., Zanic-Grubisic T., Maysinger D. Differential regulation of JNK activation and MKP-1 expression by peroxovanadium complexes. Neurochem. Int. 2001, 38:341-347.
16. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., McClanahan T., Murphy E., Yuan W., Wagner S.N., Barrera J.L., Mohar A., Verástegui E., Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
17. Yasuoka H., Kodama R., Tsujimoto M., Yoshidome K., Akamatsu H., Nakahara M., Inagaki M., Sanke T., Nakamura Y. Neuropilin-2 expression in breast cancer: correlation with lymph node metastasis, poor prognosis, and regulation of CXCR4 expression. BMC Cancer 2009, 7(9):220.
18. Tufvesson E., Westergren-Thorsson G. Tumour necrosis factor-alpha interacts with biglycan and decorin. FEBS Lett. 2002, 23:124-128.
19. Mauviel A., Santra M., Chen Y.Q., Uitto J., Iozzo R.V. Transcriptional regulation of decorin gene expression. Induction by quiescence and repression by tumor necrosis factor-alpha. J. Biol. Chem. 1995, 12:11692-11700.
20. Henderson B.E., Ross R.K., Pike M.C. Hormonal chemoprevention of cancer in women. Science 1993, 259:633-638.
21. Greenberg P.A., Hortobagyi G.N., Smith T.L., Ziegler L.D., Frye D.K., Buzdar A.U. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J. Clin. Oncol. 1996, 14:2197-2205.
22. Ishizawar R., Parsons S.J. c-Src and cooperating partners in human cancer. Cancer Cell 2004, 6:209-214.
23. Egberts J.H., Cloosters V., Noack A., Schniewind B., Thon L., Klose S., Kettler B., von Forstner C., Kneitz C., Tepel J., Adam D., Wajant H., Kalthoff H., Trauzold A. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 2008, 68:1443-1450.
24. Kulbe H., Thompson R., Wilson J.L., Robinson S., Hagemann T., Fatah R., Gould D., Ayhan A., Balkwill F. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res. 2007, 67:585-592.
25. Kulbe H., Hagemann T., Szlosarek P.W., Balkwill F.R., Wilson J.L. The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. Cancer Res. 2005, 65:10355-10362.
26. Choo M.K., Sakurai H., Koizumi K., Saiki I. Stimulation of cultured colon 26 cells with TNF-alpha promotes lung metastasis through the extracellular signal-regulated kinase pathway. Cancer Lett. 2005, 8:47-56.
27. Troup S., Njue C., Kliewer E.V., Parisien M., Roskelley C., Chakravarti S., Roughley P.J., Murphy L.C., Watson P.H. Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin. Cancer Res. 2003, 9:207-214.
28. Shintani K., Matsumine A., Kusuzaki K., Morikawa J., Matsubara T., Wakabayashi T., Araki K., Satonaka H., Wakabayashi H., Iino T., Uchida A. Decorin suppresses lung metastases of murine osteosarcoma. Oncol. Rep. 2008, 19:1533-1539.
29. Madhusudan S., Foster M., Muthuramalingam S.R., Braybrooke J.P., Wilner S., Kaur K., Han C., Hoare S., Balkwill F., Talbot D.C., Ganesan T.S., Harris A.L. A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin. Cancer Res. 2004, 10:6528-6534.
30. Madhusudan S., Muthuramalingam S.R., Braybrooke J.P., Wilner S., Kaur K., Han C., Hoare S., Balkwill F., Ganesan T.S. Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. J. Clin. Oncol. 2005, 23:5950-5959.
31. Brown E.R., Charles K.A., Hoare S.A., Rye R.L., Jodrell D.I., Aird R.E., Vora R., Prabhakar U., Nakada M., Corringham R.E., DeWitte M., Sturgeon C., Propper D., Balkwill F.R., Smyth J.F. A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann. Oncol. 2008, 19:1340-1346.
32. Harrison M.L., Obermueller E., Maisey N.R., Hoare S., Edmonds K., Li N.F., Chao D., Hall K., Lee C., Timotheadou E., Charles K., Ahern R., King D.M., Eisen T., Corringham R., DeWitte M., Balkwill F., Gore M. Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J. Clin. Oncol. 2007, 10:4542-4549.